Description: Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of pain and other central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of pain in patients with complex regional pain syndrome; and AXS-05 for the treatment of agitation in patients with Alzheimer's disease and treatment resistant depression. The company is also developing AXS-02 for the treatment of knee osteoarthritis and chronic low back pain, as well as a preclinical development program AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.
Home Page: www.axsome.com
AXSM Technical Analysis
22 Cortlandt Street
New York,
NY
10007
United States
Phone:
212 332 3241
Officers
| Name | Title |
|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & Pres |
| Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer |
| Mr. Mark L. Jacobson | COO & Sec. |
| Mr. Hunter Murdock Esq. | Exec. VP of Legal & Compliance |
| Dr. Amanda Jones Pharm.D. | Sr. VP of Clinical Devel. |
| Ms. Lori Englebert M.B.A. | Exec. VP of Commercial & Bus. Devel. |
| Mr. Kevin Laliberte Pharm.D. | Exec. VP of Product Strategy |
| Joseph Debrah-Afful CPA, M.B.A. | Director of Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.6587 |
| Price-to-Sales TTM: | 134.7595 |
| IPO Date: | 2015-11-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 352 |